Suppr超能文献

用邻近诱导调节剂靶向tau蛋白:对抗tau蛋白病的新前沿。

Targeting Tau Protein with Proximity Inducing Modulators: A New Frontier to Combat Tauopathies.

作者信息

Uliassi Elisa, Bolognesi Maria Laura, Milelli Andrea

机构信息

Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, Via Belmeloro 6, Bologna 40126, Italy.

Department for Life Quality Studies, Alma Mater Studiorum - University of Bologna, Corso d'Augusto 237, Rimini 47921, Italy.

出版信息

ACS Pharmacol Transl Sci. 2025 Feb 10;8(3):654-672. doi: 10.1021/acsptsci.4c00733. eCollection 2025 Mar 14.

Abstract

Dysregulation of correct protein tau homeostasis represents the seed for the development of several devastating central nervous system disorders, known as tauopathies, that affect millions of people worldwide. Despite massive public and private support to research funding, these diseases still represent unmet medical needs. In fact, the tau-targeting tools developed to date have failed to translate into the clinic. Recently, taking advantage of the modes that nature uses to mediate the flow of information in cells, researchers have developed a new class of molecules, called proximity-inducing modulators, which exploit spatial proximity to modulate protein function(s) and redirect cellular processes. In this perspective, after a brief discussion about tau protein and the classic tau-targeting approaches, we will discuss the different classes of proximity-inducing modulators developed so far and highlight the applications to modulate tau protein's function and tau-induced toxicity.

摘要

正确的蛋白质tau稳态失调是几种毁灭性中枢神经系统疾病(即tau蛋白病)发展的根源,这些疾病影响着全球数百万人。尽管获得了大量公共和私人资金支持用于研究,但这些疾病仍存在未满足的医疗需求。事实上,迄今为止开发的靶向tau蛋白的工具未能转化为临床应用。最近,研究人员利用自然界中用于介导细胞内信息流的方式,开发了一类新的分子,称为邻近诱导调节剂,这类分子利用空间邻近性来调节蛋白质功能并重新引导细胞过程。从这个角度来看,在简要讨论tau蛋白和经典的靶向tau蛋白的方法之后,我们将讨论迄今为止开发的不同类别的邻近诱导调节剂,并强调其在调节tau蛋白功能和tau诱导的毒性方面的应用。

相似文献

1
Targeting Tau Protein with Proximity Inducing Modulators: A New Frontier to Combat Tauopathies.
ACS Pharmacol Transl Sci. 2025 Feb 10;8(3):654-672. doi: 10.1021/acsptsci.4c00733. eCollection 2025 Mar 14.
2
The Lived Experience of Autistic Adults in Employment: A Systematic Search and Synthesis.
Autism Adulthood. 2024 Dec 2;6(4):495-509. doi: 10.1089/aut.2022.0114. eCollection 2024 Dec.
3
The Black Book of Psychotropic Dosing and Monitoring.
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
6
Psychological therapies for post-traumatic stress disorder and comorbid substance use disorder.
Cochrane Database Syst Rev. 2016 Apr 4;4(4):CD010204. doi: 10.1002/14651858.CD010204.pub2.
7
Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men.
Cochrane Database Syst Rev. 2008 Jul 16(3):CD001230. doi: 10.1002/14651858.CD001230.pub2.
8
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
9
Chemical Strategies to Modulate and Manipulate RNA Epigenetic Modifications.
Acc Chem Res. 2025 Jun 3;58(11):1727-1741. doi: 10.1021/acs.accounts.4c00844. Epub 2025 Mar 18.
10
Active body surface warming systems for preventing complications caused by inadvertent perioperative hypothermia in adults.
Cochrane Database Syst Rev. 2016 Apr 21;4(4):CD009016. doi: 10.1002/14651858.CD009016.pub2.

引用本文的文献

1
PROTAC Technology as a New Tool for Modern Pharmacotherapy.
Molecules. 2025 May 11;30(10):2123. doi: 10.3390/molecules30102123.
2
Medicinal Chemistry: A Key Driver in Achieving the Global Sustainable Development Goals.
J Med Chem. 2025 Apr 10;68(7):6916-6931. doi: 10.1021/acs.jmedchem.4c03016. Epub 2025 Mar 20.

本文引用的文献

1
Modulating Phosphorylation by Proximity-Inducing Modalities for Cancer Therapy.
J Med Chem. 2024 Dec 26;67(24):21695-21716. doi: 10.1021/acs.jmedchem.4c02624. Epub 2024 Dec 9.
2
Are lecanemab and donanemab disease-modifying therapies?
Alzheimers Dement. 2024 Sep;20(9):6659-6661. doi: 10.1002/alz.14114. Epub 2024 Aug 3.
3
FDA approves third anti-amyloid antibody for Alzheimer disease.
Nat Rev Drug Discov. 2024 Aug;23(8):571. doi: 10.1038/d41573-024-00116-1.
4
A new tau dephosphorylation-targeting chimera for the treatment of tauopathies.
Acta Pharmacol Sin. 2024 Nov;45(11):2267-2276. doi: 10.1038/s41401-024-01326-4. Epub 2024 Jul 2.
6
Cost-Effectiveness of Lecanemab for Individuals With Early-Stage Alzheimer Disease.
Neurology. 2024 Apr 9;102(7):e209218. doi: 10.1212/WNL.0000000000209218. Epub 2024 Mar 14.
7
Proximity-Induced Pharmacology for Amyloid-Related Diseases.
Cells. 2024 Mar 4;13(5):449. doi: 10.3390/cells13050449.
8
Potential impact of unblinding on observed treatment effects in Alzheimer's disease trials.
Alzheimers Dement. 2024 Apr;20(4):3119-3125. doi: 10.1002/alz.13690. Epub 2024 Feb 21.
9
Generation of tau dephosphorylation-targeting chimeras for the treatment of Alzheimer's disease and related tauopathies.
Sci Bull (Beijing). 2024 Apr 30;69(8):1137-1152. doi: 10.1016/j.scib.2024.01.019. Epub 2024 Jan 19.
10
A review of the flortaucipir literature for positron emission tomography imaging of tau neurofibrillary tangles.
Brain Commun. 2023 Nov 16;6(1):fcad305. doi: 10.1093/braincomms/fcad305. eCollection 2024.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验